Bayer Protests 'Incomprehensible' German Decision on Stivarga In mCRC
This article was originally published in Scrip
Executive Summary
A decision by the German health technology assessment agency IQWiG that new analysis provided by Bayer of Stivarga (regorafenib) in metastatic colorectal cancer (mCRC) result in the product's disadvantages outweighing its benefits "is essentially incomprehensible to Bayer," the German pharma told Scrip.
You may also be interested in...
Bayer Set To Sew Up HCC Market As RESORCE Hits Endpoint
Top-line success for Bayer's trial of Stivarga in advanced liver cancer in patients who have progressed on its other therapy Nexavar gives the company an opportunity to dominate the market, but Stivarga's potential may be overshadowed by its drawbacks and looming competition.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.